Lexapro

PreclinicalSmall molecule

SShirley Ryan AbilityLab

Lexapro is one of 102 small molecule programs targeting Anxiety. It is currently in Preclinical.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnxietyActive, not recruiting

AsthmaActive, not recruiting

DepressionTerminated

Major DepressionCompleted

Irritable Bowel Syndrome With ConstipationRecruiting

AnxietyPreclinical

Active, not recruiting

AsthmaPreclinical

Active, not recruiting

DepressionPreclinical

Terminated

Major DepressionPreclinical

Completed

Irritable Bowel Syndrome With ConstipationPreclinical

Recruiting

Competition

Competitive Landscape

161 competitors in Asthma

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

Arcoxia

Novartis

Preclinical

—3

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 4

DUPIXENT

Regeneron

Preclinical

1 5

Paracetamol

GSK

Preclinical

1 6

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 7

Aclidinium Bromide

AstraZeneca

Preclinical

—8

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 9

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Biological Drug

UUniversitaire Ziekenhuizen KU Leuven

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalRecruiting

Irritable Bowel Syndrome With Constipation

NCT05519683

Clinical

Trials by Indication[1]

Anxiety1 trial

Exercise and Pharmacotherapy for Anxiety in Cardiac Patients

Completed·—·N/A·NCT02516332·128 enrolled

Epilepsy1 trial

Lexapro for Major Depression in Patients With Epilepsy

Terminated·WWeill Medical College of Cornell University·Phase 4·NCT01244724·26 enrolled

Schizophrenia1 trial

Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype

Unknown status·NNational Taiwan University Hospital·Phase 4·NCT01078870·75 enrolled

Motor Function1 trial

Serotonergic Modulation of Motor Function in Subacute and Chronic SCI

Unknown status·SShirley Ryan AbilityLab·Phase 1·NCT01788969·42 enrolled

Depression1 trial

Combination Lexapro and Massage for Treatment of Depression in Older Adults

Terminated·—·N/A·NCT00643162·17 enrolled

6 more indications

Asthma1 trial

Impact of Caregiver Depression on Asthma in the Child

Completed·UUniversity of Texas Southwestern Medical Center··NCT00223288·175 enrolled

Dysthymic Disorder1 trial

Escitalopram in the Treatment of Dysthymic Disorder, Double Blind

Completed·SSt. Luke's-Roosevelt Hospital Center·Phase 4·NCT00220701·36 enrolled

Major Depression1 trial

fMRI Studies of Emotional Brain Circuitry in People With Major Depression

Completed·WWashington University School of Medicine·N/A·NCT00749125·99 enrolled

Spinal Cord Injury1 trial

Monoaminergic Modulation of Motor Function in Subacute Incomplete Spinal Cord Injury (SCI)

Unknown status·SShirley Ryan AbilityLab·Phase 1·NCT01753882·88 enrolled

Panic Disorder1 trial

Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder

Completed·SSamsung Medical Center·Phase 4·NCT00767871·46 enrolled

Irritable Bowel Syndrome With Constipation1 trial

Effects of Home-based TEA for Abdominal Pain in Patients With Irritable Bowel Syndrome (IBS)

Recruiting·UUniversity of Michigan·Preclinical·NCT05519683·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Lexapro. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lexapro compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lexapro. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shirley Ryan AbilityLab company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShirley Ryan AbilityLab

Lexapro

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Anxiety1 trial

Epilepsy1 trial

Schizophrenia1 trial

Motor Function1 trial

Depression1 trial

Asthma1 trial

Dysthymic Disorder1 trial

Major Depression1 trial

Spinal Cord Injury1 trial

Panic Disorder1 trial

Irritable Bowel Syndrome With Constipation1 trial

References

Drug Info

Quick Facts

Related News